Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD) had its target price boosted by Cantor Fitzgerald from $155.00 to $175.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on GILD. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Barclays decreased their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Zacks Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. BMO Capital Markets reiterated an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $185.00 price target on shares of Gilead Sciences in a research note on Friday, October 23rd. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $169.19.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $170.68 on Friday. Gilead Sciences has a one year low of $114.02 and a one year high of $175.65. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The business has a fifty day moving average price of $150.87 and a 200-day moving average price of $139.79.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.47 earnings per share. Analysts anticipate that Gilead Sciences will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares in the company, valued at $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the transaction, the insider directly owned 118,234 shares in the company, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently modified their holdings of the stock. Client 1ST Advisory Group LLC grew its holdings in Gilead Sciences by 4.0% during the 3rd quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 69 shares in the last quarter. Grove Bank & Trust boosted its position in shares of Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after acquiring an additional 74 shares during the last quarter. Financial Connections Group Inc. grew its stake in Gilead Sciences by 30.2% during the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares in the last quarter. Wilkerson Advisory Group LLC increased its holdings in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 78 shares during the last quarter. Finally, HBW Advisory Services LLC lifted its stake in Gilead Sciences by 2.4% in the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 79 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.